Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Dec 24;23(2):143–150. doi: 10.1016/j.cllc.2021.12.005

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 The Authors. Published by Elsevier Inc.

Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

PMC Copyright notice

PFS and OS according to ICI treatment schedule (red, Standard dose cohort; blue, Extended interval dosing cohort; two-sided log-rank test). For the survival analysis, patients with ICI-related toxicity and/or PD before start of the escalation window were excluded from the standard dose group. (a) Patients treated with pembrolizumab monotherapy (n = 54). (b) Patients treated with chemo-ICI combination therapy (n = 15; EI dosing cohort only). (c) Patients treated with nivolumab monotherapy (n = 34). (d) Patients treated with durvalumab (n = 64).